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Recurrent Her-2 positive occult breast 
cancer presenting with zosteriform 
cutaneous metastases: a case report
ABSTRACT
Various cutaneous metastasis patterns are described in breast cancer. Zosteriform metastases are rare cutane-
ous metastases, which appear in a dermatomal distribution. A 66-year woman presented with a 1-month history 
of nodular lesions on the left posterior hemithorax area. Biopsy was reported as human epidermal growth factor 
receptor (Her) 2 positive, hormone receptor-negative breast carcinoma metastasis. Dual blockade therapy target-
ing Her-2 overexpression was initiated for the patient. Treatment response was obtained after 3 cycles. There was 
a significant improvement in skin lesions. Zosteriform cutaneous metastases can be the early sign of systemic 
spread and can show an initial response to therapy. Therefore, physicians should perform an exhaustive physical 
examination including that of skin. 
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Introduction
Cutaneous metastases of solid malignancy are 
relatively uncommon, with an incidence ranging from 
0.7 to 10.4% [1]. The incidence of breast carcinoma cu-
taneous metastases is 23.9% [2]. Most of the cutaneous 
metastases appear as adjacent lesions concerning the 
breast primary. Various cutaneous metastasis patterns 
such as zosteriform, ulcers, erysipelas, tinea infections, 
erythema annulare are described, a nodular pattern is the 
most common presentation [3]. The sites of cutaneous 
metastases are the abdomen and chest wall (most com-
mon), head/neck region, and extremities. Breast cancer 
tends to metastasize less frequently to the lower abdo-
men, back, and upper arms; and unusual to the perianal 
region, buttocks, eyelids, and lower extremities [4]. Solid 
cancers’ skin metastases are related to the advanced stage 
of cancer, whereas breast cancers’ cutaneous metastases 
can appear in locally advanced disease [5]. In one study, 
it was found that skin metastasis emerged as the initial 
finding in 12% of breast cancer patients [6]. However, 
data on the frequency of presentation with skin metasta-
ses in patients with recurrent breast cancer are limited.
Diffuse skin metastases without distant spread occur 
in human epidermal growth factor receptor (Her) 2-am-
plified disease [6]. Uncommonly, cutaneous metastases 
can be a sign of cancer recurrence. Often, the period 
from the initial diagnosis to cutaneous metastasis is 
5 years [7]. Zosteriform metastases are rare cutaneous 
metastases, which appear in a dermatomal distribution 
[8]. This research aims to present a case of recurrent 
Her-2 positive breast cancer who presented with zos-
teriform skin metastases 7 years later.
Case presentation
A 66-year woman presented with a 1-month history 
of nodular lesions on the left posterior hemithorax area. 
In medical history, she had left mastectomy after neo-
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adjuvant chemotherapy for breast cancer 7 years ago. 
Family history was unremarkable. Vital findings were 
stable. On physical examination, there were pink-red 
and black raised skin bumps that were distributed 
along a single dermatome in the posterior of the left 
hemithorax (Fig. 1). There was no left breast tissue, 
there was an approximately 20 cm incision line in this 
area. CA 15.3 was 12.6 U/mL (0–35) and there was no 
abnormal value in other laboratory levels. Biopsy was 
taken from these lesions. The result was reported as Her 
2 positive, hormone receptor-negative breast carcinoma 
metastasis. Positron Emission Tomography-Computed 
Tomography (PET-BT) findings are as follows: left 
breast was not observed, there was no mass in the right 
breast. There were expansive skin lesions of 17 × 11 mm 
(SUV max: 5.77) in the left posterolateral hemithorax 
and 8 × 5 mm (SUV max: 3.48) in the medial. Brain 
magnetic resonance imaging was performed, and no 
lesions were detected. Although there is no mass in the 
patient’s right breast, according to the patient’s history 
of breast cancer and the biopsy result, occult breast 
cancer was diagnosed. Skin lesions were evaluated as 
zosteriform cutaneous metastasis. Echocardiography 
was performed before treatment and the ejection 
fraction was 60%. Dual blockade therapy targeting 
Her-2 overexpression was initiated for the patient. Tras-
tuzumab (8 mg/kg loading dose, 6 mg/kg maintenance 
dose, every 3 weeks), pertuzumab (840 mg loading 
dose, 420 mg maintenance dose, every 3 weeks), and 
docetaxel (75 mg/m2, every 3 weeks) were initiated. 
Treatment response was obtained after 3 cycles. There 
was a significant improvement in skin lesions (Fig. 2). 
After 6 cycles were completed, maintenance treatment 
was started with trastuzumab (6 mg/kg, every 3 weeks) 
and pertuzumab (420 mg, every 3 weeks). The patient 
was observed with no evidence of progressive disease.
Discussion
Cutaneous metastases though rare can be the 
first sign of cancer recurrence. Zosteriform metas-
tases are rare cutaneous metastases, which appear 
in a dermatomal distribution. This case presented 
with zosteriform cutaneous metastasis in the back 
from Her-2 positive breast cancer occurring after 
7 years later adjuvant anthracycline-based regimen 
plus trastuzumab therapy. Most of the cutaneous 
metastases occur as direct lesions in relation to the 
breast primary. Zosteriform cutaneous metastases 
may rarely be in the form of distant metastases in 
the back, as in this case presented. The mechanism 
of zosteriform distribution is unknown. Koebneriza-
tion at the site of previous zoster infection and neural 
spread through the dorsal ganglia are theories in 
Figure 1. Presentation of recurrent breast cancer with 
zosteriform cutaneous metastases 
Figure 2. Regression of treatment-related zosteriform 
cutaneous metastases
the pathophysiology of zosteriform metastasis [9]. 
The skin does not appear to be the target organ for 
metastasis development. Cutaneous metastasis is a rare 
clinical sign. Usually, the development of skin metas-
tases is poorly prognostic [10]. Cutaneous metastases 
result from hematogenous, lymphatic, or contiguous dis-
semination [10]. A review of the literature demonstrated 
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that the incidence of cutaneous metastasis ranges from 
0.7% to 10% [1]. Cutaneous metastases may present dif-
ferent appearances in breast cancer. The most common 
form is the nodule pattern and is seen in the chest wall 
and abdomen. The sizes of these nodules vary between 
1 and 3 cm. and appear as single or multiple hardened 
lesions located on the dermis and subcutaneous tissue. 
Several cases of cutaneous metastases after or during 
treatment have been defined in the literature [11, 12]. Here-
in a case is described in which a patient with Her2-positive 
metastatic breast cancer had zosteriform cutaneous pro-
gression 7 years later treatment. To the authors’ knowledge, 
there was no such case in the literature. In brain metastases, 
the effectiveness of monoclonal antibodies is generally 
limited due to the brain-blood barrier or to the so-called 
“immune privilege” of the brain [13, 14]. Interestingly, im-
mune privilege has been defined also in the skin [15]. It has 
been claimed that tumour cells are a sanctuary-like region 
in the cutaneous microenvironment [16]. 
Zosteriform metastases are a rare clinical presenta-
tion of cutaneous metastases and can be the early sign of 
systemic spread. Zosteriform cutaneous metastases can 
show an initial response to therapy. Therefore, physi-
cians should perform an exhaustive physical examination 
including that of skin. 
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